NICE (Single) Technology Appraisal Guidance 127: Natalizumab
for the treatment of adults with highly active relapsing-remitting
This NICE guidance was published on
22 August 2007. The web reference for the appraisal and other
related documents is:
NHSScotlandshould note that:
1. Recommendations of NICE Single
Technology Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice
(329/06) on this medication for this indication in September 2007.
This stated that:
Natalizumab (Tysabri®) is accepted for
restricted use within NHSScotland as single disease modifying
therapy in highly active relapsing remitting multiple sclerosis
(RRMS) only in patients with rapidly evolving severe RRMS defined
by two or more disabling relapses in one year and with one or more
gadolinium-enhancing lesions on brain magnetic resonance imaging
(MRI) or a significant increase in T2 lesion load compared with a
Access the advice of SMC:
There is no material difference between
the recommendations of the NICE STA and SMC.
Published Date: 22 August 2007